Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension study

Next Previous
Search
Trial Profile

A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Adverse reactions
  • Acronyms COMPOSE V
  • Sponsors Shionogi

    • Most Recent Events

    • 02 Oct 2017 Results published in the Journal of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2016 According to a Shionogi media release, the New Drug Application (NDA) submitted in the U.S. for naldemedine, a once-daily, oral 0.2 mg tablet, has been accepted for review and the target action date under the Prescription Drug User Fee Act (PDUFA) is March 23, 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top